THE European Medicines Agency’s
Committee for Medicinal Products
for Human Use (CHMP) has
recommended the approval of
insulin degludec, a new basal
analogue insulin for the treatment
of diabetes mellitus in adults.
The drug is introduced in a
pre-filled pen in two formulations –
100 units/ml and 200 units/ml, and
is the first insulin approved in
Europe at a higher strength than
the EU-wide standard of 100 units/ml.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Oct 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.